US 12,441,717 B2
Crystal form of polycyclic anaplastic lymphoma kinase inhibitor
Guohui Han, Jinan (CN); and Haibo Wang, Jinan (CN)
Assigned to SHANDONG XUANZHU PHARMA CO., LTD., Jinan (CN); and XUANZHU BIOPHARMACEUTICAL CO., LTD., Shijiazhuang (CN)
Appl. No. 17/793,275
Filed by SHANDONG XUANZHU PHARMA CO., LTD., Jinan (CN); and XUANZHU BIOPHARMACEUTICAL CO., LTD., Shijiazhuang (CN)
PCT Filed Jan. 15, 2021, PCT No. PCT/CN2021/072088
§ 371(c)(1), (2) Date Jul. 15, 2022,
PCT Pub. No. WO2021/143819, PCT Pub. Date Jul. 22, 2021.
Claims priority of application No. 202010051060.1 (CN), filed on Jan. 17, 2020.
Prior Publication US 2023/0348443 A1, Nov. 2, 2023
Int. Cl. C07D 405/14 (2006.01)
CPC C07D 405/14 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
OG exemplary drawing
 
1. Crystal form B of a compound of formula (1), characterized by an X-ray powder diffraction pattern comprising characteristic peaks at 11.9±0.2°, 14.0±0.2°, 15.2±0.2°, 17.2±0.2°, 17.5±0.2°, and 21.5±0.2° expressed as 2θ angles using Cu-Kα radiation;

OG Complex Work Unit Chemistry